

Longer Term Investments

Obesity

Chief Investment Office GWM | 28 August 2019 1:24 pm BST

Lachlan Towart, Analyst; Andreas A. Tomaschett, CFA, Analyst

- Urbanization and rising per capita GDP in emerging markets will contribute to a greater prevalence of obesity globally in the coming decades.
- Companies in the food and beverage, fitness and sportswear industries (prevention), and the healthcare sector (treatment) can benefit from this long-term trend: the most attractive and investable related markets are expected to see medium-to-high single-digit growth rates. In the healthcare industry, we prefer investment opportunities in diabetes treatment and dialysis services, as drugs to treat obesity have thus far been relative commercial failures.
- The theme benefits from defensive growth with predictable volume trends, potentially high returns on capital and growing dividends.
- We recommend investing in a diversified portfolio across the consumer and healthcare industries to take advantage of the obesity theme, while minimizing company-specific risks associated with the failure of drugs in development.


Today there are 650 million obese people in the world, out of nearly two billion overweight people. Western economies are most associated with the obesity epidemic, but it is no longer just a developed-world problem. Rapidly urbanizing populations and increasing per capita GDP are leading to ever-higher calorie consumption in emerging markets. We expect these economies to fuel the increase in the number of obese and overweight people in the next decade.

According to McKinsey, the economic cost of obesity approaches 3% of global GDP. Despite government policy responses and greater individual awareness, global obesity levels look set to keep rising. This creates a large and growing opportunity for companies that provide products to help prevent or reduce obesity and those that treat its consequences. We have identified investment opportunities related to obesity under two broad categories:

- **Prevention:** Companies that offer healthier food, fitness products and sportswear, as well as the vitamin and supplement industry.
- **Treatment:** Companies that offer drugs, medical products and services to reduce weight or treat obesity-related conditions such as diabetes.

Introduction to the Longer Term Investments (LTI) series

- **The Longer Term Investments (LTI)** series contains thematic investment ideas based on long term structural developments.
- Secular trends such as population growth, ageing, and increased urbanization create a variety of longer term investment opportunities.
- These investment opportunities are influenced by the interplay of technological advancement, resource scarcity, and the societal changes.
- Investors willing to invest over multiple business cycles can benefit from potential mispricings created by the typically shorter term focus of stock markets.



Attractive investment opportunities lie in the health and wellness food industry, and those that treat diabetes and offer dialysis services. The theme benefits from volume growth forecast in the medium-to-high single digits in percentage terms. It is defensive, displays stable earnings growth and potentially high returns on capital, growing dividends, and is insensitive to the economic cycle, making it attractive for quality-focused growth investors.

The obesity epidemic

Obesity has reached epidemic proportions in many Western countries (Fig. 1). According to the most recent *World Health Organization* (WHO) figures, in 2016 more than 1.9 billion adults were overweight, of which 650 million were obese. These figures are consistent with a landmark study published in the medical journal *The Lancet* in 2014, which found 671 million people were obese in 2013, out of a global overweight population of some 2.1 billion. This represents a more than doubling of the obese population since 1980.

More than 40% of the world could be overweight by 2030

Based on the latest WHO data, in 2016 13% of the global adult population was obese and 39% was overweight. Among children over five and adolescents, 18% were overweight. On current trends, by 2030 the combined global prevalence of obesity and overweight could exceed 40% by 2030, while US obesity rates could pass 50%.


Obesity is most prevalent in the developed world: for example, the Centers for Disease Control and Prevention (CDC) estimates that nearly 40% of US adults, or 93 million people, are obese, and no state has an obesity rate below 20%. The trend to higher obesity rates in the US continues relentlessly upward (Fig. 2). But obesity is not just a developed-world problem: we expect the emerging world to account for most of the increase in the number of obese people over the next two decades. The two most important drivers of rising EM obesity rates are increasing urbanization and rising per capita GDP.

Urbanization and rising per capita GDP fuel EM obesity

The rising prevalence of obesity in emerging markets (EM) stems primarily from rapid urbanization, in our view. Almost 70% of the world's population will live in cities by 2050 (Fig. 3), according to UN estimates, and the urban lifestyle contributes to both of the primary causes of obesity: a more sedentary lifestyle and a more "Western" diet that includes higher amounts of fat, sugar and protein (the so-called "nutrition transition"). City jobs are typically less labor intensive than those in the country, and workers are less likely to walk to and from work, reducing physical exercise levels. Cities also provide more dietary temptations: easier access to fast food, restaurants and bars. Several emerging countries already have rich-world levels of obesity (Fig. 4), and we see worrying trends in others. For example, in China the overall obesity rate is estimated at 7%, yet overweight and obesity rates in major coastal cities approach Western levels – a worrying leading indicator.


As per capita GDP rises, calorie consumption increases. The implication appears clear: EM obesity rates are likely to catch up to those

Fig. 1: Obesity prevalence globally
% of male population obese, 2016




Source: WHO, as of May 2018

Fig. 2: US obesity rates continue to increase
% of population obese, 2011 & 2017



Source: CDC, as of August 2018. Note: prevalence of self-reported obesity. Not comparable to pre-2011 data due to methodology change.

Fig. 3: Urban and rural populations
1950-2050E (billions)



Source: United Nations, UBS estimates, as of 2019

in developed markets as EM populations migrate to the cities, their standards of living rise and their exercise levels fall (Fig. 5).

In developed markets, a greater emphasis on healthy diets at both the individual and societal level has led to some early positive signs, such as lower consumption of sugar and calories among millennials. However, habits are hard to change, and it is too soon to see a downward trend in obesity statistics. Obesity rates remain elevated in children: 18% of girls and 19% of boys aged 5–19 were estimated to be overweight in 2016, compared to rates below 5% in the 1970's. Even among the under-fives, the WHO estimates there were 41 million overweight toddlers in 2016. Evidence suggests that obese children become obese adults, so we can expect the current trends to continue as today's children age. All told, we anticipate a continued rise in the number of obese people, albeit at a slower rate than in the "catch-up" EM population.

Economic costs and public policy

Obesity imposes a significant cost on both the individual and society. An estimated 3.4m people die each year as a result of being overweight or obese, making a high Body-Mass Index (BMI) the fifth-highest risk factor for mortality globally (source: *The Lancet*).


The economic costs are significant and growing. A 2009 study noted that total healthcare costs for obese patients are 42% higher for obese and 81% higher for severely obese patients than for those with normal BMI (source: *Health Affairs*). The average annual expenses of an obese person on Medicare are USD 4,870 compared to USD 3,400 for an average-weight person. Direct costs alone, including diagnostics, treatment and preventive services, have been estimated at 1%–3% of healthcare costs for most countries, or 5–10% in the US, using OECD data. In the US this translates into an estimated USD 200 billion of direct medical cost for managing obesity, according to the *Campaign to end Obesity*.

Healthcare budgets increasingly stretched

A widely discussed McKinsey study estimated the total economic cost of obesity-related conditions at nearly 3% of global GDP, including lost productivity due to disability or death. However, this may still underestimate the total cost since many medical costs that may ultimately stem from obesity are recorded as other problems at the point of care: the *Campaign to End Obesity* has argued that current estimates may underestimate eventual government spending on obesity by as much as 50%.


Given that healthcare budgets are increasingly stretched, such costs argue for a policy-based response to reduce the prevalence of obesity and to better treat it. Recognizing that obesity is preventable in principle, some governments have explored fiscal measures and regulations to reduce the consumption of sugar and fat, but early data suggest only a marginal impact on consumer behavior, and it is too soon to see any resulting changes in weight trends. The number of policies implemented to date is small. At an individual level there is increasing interest in healthier eating, although this has done little to reverse aggregate weight trends.

Fig. 4: Obesity rates by country
Percent of obese adults, selected countries



Source: OECD, as of 2017. Note: adults aged 15 or over

Fig. 5: GDP per capita vs. calorie consumption



Source: FAO Statistics Division, World Development Indicators, Bernstein Analysis, as of 2013

Obesity-related investment opportunities

We analyze investment opportunities related to obesity under two broad categories:

- **Prevention:** Companies offering healthier food, fitness products and sportswear, as well as the vitamin and supplement industry.
- **Treatment:** Companies offering drugs, medical products and services to reduce weight or treat obesity-related conditions such as diabetes.

We view the market for professional weight-loss companies as less attractive, due to low barriers to entry and the rise of do-it-yourself approaches to weight loss. Low barriers to entry also reduce the attractiveness of the fitness and health club market, in our view.

We are still taking a wait-and-see approach to the emerging pharma companies developing prescription drugs aimed at reducing weight. Historically, this market has failed to meet expectations due to side effects, poor patient compliance and unfavorable insurance coverage. However, we recognize that the increasing acceptance of obesity as a medical condition could lead to increased acceptance of pharmacological treatment for weight loss, particularly among severely obese patients with other medical complications.

Balanced diet to avoid obesity

Unhealthy lifestyle

Unbalanced diets, combined with insufficient physical activity, are the key causes of obesity. Global calorie consumption has continuously increased, in particular in developed markets (Fig. 5), due to increased food availability, cheaper food, and more sugar and processed / fast food consumption. This trend is likely to continue as the larger numbers of middle-class consumers in emerging countries adapt to Western lifestyles. Cities continue to expand as employees move in to take service industry jobs, leaving behind the more physical agricultural and manufacturing sectors. People become richer and take advantage of entertainment opportunities in the cities provided by cinemas, restaurants and bars. As a result, people consume more calories than they burn through physical activity.

Food industry: Focus on better-for-you food

A balanced diet remains one of the key ways to reduce obesity. The global health and wellness food market is currently almost USD 800bn, and is expected to grow by mid single digits according to a range of industry estimates. In our view, food producers and retailers need to be and are becoming part of the solution in the fight against obesity. They are doing so in the following four ways: First, they are expanding their product offering into healthier categories, e.g. fresh and organic food. Second, food producers are reformulating the nutritional profile of their products, reducing their fat and sodium content, etc. Reducing saturated and trans fats should help mitigate the risk of obesity. Third, companies are disclosing more on the packaging of their products regarding ingredients. The labeling shows the percentage of fat, sugar and calories as a percentage of a recommended daily diet the product contains. Fourth, package sizes have

Fig. 6: Health & wellness, insulin and dialysis the most investable opportunities

Market size in USD bn, annual growth rates 2018

Market opportunity	Current size (USD bn)	Long term growth	Investability
Obesity prevention			
Health & wellness food & beverage	800	Mid single digit	High
Athletic and apparel	300	Mid single digit	High
Vitamins, minerals & supplements	110	High single digit	Low
Fitness & health clubs	80	Mid single digit	Low
US Consumer weight-loss products	60 - 70	Mid single digit	Low
Obesity treatment			
Dialysis products & services	40 - 45	Mid single digit	High
Insulin & GLP-1	30	Mid single digit	High
Sleep apnea	5	Mid-high single digit	Medium
Bariatric surgery	1	Mid-high single digit	Low
Prescription weight-loss drugs	1	Mid-high single digit	Low

Source: UBS estimates, as of August 2019.

been made smaller to reduce overconsumption. All four measures should help to fight obesity and benefit food companies focusing on healthier food.

Beverage industry: Focus on reduced and non-calorie drinks

Soft drink beverage companies have increased their offering of lower and non-calorie drinks. Brewers have enhanced their portfolio with products offering reduced alcohol content. The "still" beverage categories are the fastest growing in the industry. Spring water probably offers the highest "nutritional" effect. However, carbonated soft drinks remain the largest categories for the biggest beverage companies, PepsiCo and Coca-Cola. As increased sugar consumption leads to obesity, the emphasis on reduced and non-calorie offerings has increased. As they become more cautious about artificial sweeteners, consumers are demanding natural sweeteners. But those like Stevia are currently used mainly to limit calories. Their taste effect prevents them from fully replacing artificial sweeteners or regular sugar. In our view, lower sugar consumption in beverages should reduce obesity and benefit companies focused on low-calorie or natural/organic drinks. Better labeling should increase consumer awareness and smaller package sizes should help consumers avoid overconsumption.

Regulations are only a part of the solution

As an example, Mexico, the country with the highest per capita consumption of Coca-Cola, introduced a tax on sugar a few years ago. But government regulations can only serve as a part of the solution, in our view. Consumer behavior and demand adjustments will be key. Unlike with tobacco and alcohol, food and beverage consumption per se is not bad for your health; fats and sugar do fulfill a needed function. Obesity results from overconsumption and an unbalanced diet. Government regulations and taxes may increase awareness of obesity and put pressure on food and beverage companies to reduce calories. However, every consumer decides individually what and how much to consume.

Commercial weight-loss markets

Professional weight-loss companies like Weight Watchers combine products and services such as targeted nutrition (e.g. lower-calorie food replacements) and behavioral change (e.g. classes and clubs) to promote new eating habits and better-for-you lifestyle choices. The US market is currently estimated to be worth USD 70–80bn according to industry estimates. However, several companies have been hit hard by lower consumer spending and the rise of do-it-yourself approaches. Although long-term trends should support market growth, barriers to entry are low due to increasing digitization. In particular, the number of fitness and diet apps has increased, though they could have limitations when it comes to motivating people. Nevertheless, while commercial weight-loss companies work to prevent obesity, low market barriers combined with increasing do-it-yourself dieters make it an unattractive investment market to us.

Physical activity to improve health

Several beneficiaries

Regular exercise such as walking, cycling and swimming has significant health benefits. Physical activity combined with a balanced diet plays an important role in preventing and reducing obesity. Although such activity can be performed without any financial investment, fitness centers, sportswear and apparel companies, and the sports nutrition industry can, and do, benefit from the current desire and need to keep weight off.

Fitness and health clubs

We estimate that the global industry of fitness and health clubs generates around USD 90bn in annual sales. The market is fragmented, with numerous private and local operators. Barriers to entry are low and limit pricing opportunity. Therefore, it is not an attractive investment opportunity, in our view, although it can play an important role in preventing and reducing obesity.

Sportswear and apparel

Increasing health awareness is likely to result in growing numbers of people demanding affordable equipment and apparel to engage in physical activity or sports. We estimate the global athletic and apparel industry to generate annual revenues of over USD 300bn, although it is difficult to segregate between athletic and leisure. The industry is expanding markedly both in North America and emerging markets. Footwear is growing globally at a high single-digit rate, apparel at a low-to-medium single-digit rate and sporting equipment (e.g. golf) in the low single digits in percentage terms.

Supplement industry

The vitamin, minerals and supplement industry also benefits indirectly from increased health awareness. We estimate it generates around USD 110bn in revenues annually, and is expected to grow at high-range single-digit rates according to industry estimates. An increasingly health and fitness-conscious consumer population supports long-term fundamentals. The biggest risk attaches to medical studies questioning the effectiveness of supplements. High-growth areas include sports nutrition, meal replacement and other specialty-product subsectors, which are not directly related to the fight against obesity.

Medical treatment of obesity

Obesity and being overweight are typically defined in terms of Body Mass Index (BMI), calculated as a patient's weight (in kg) divided by the square of the person's height (in m). Patients with BMI ≥ 25 are considered overweight and those with BMI ≥ 30 are defined as medically obese (Fig. 7).

Treatment for obesity begins with behavior and diet modification. For those unable to manage their weight through diet and exercise, an increasing number of medical options have become available. While the idea of a magic pill against obesity is attractive, the market for drugs to control weight has historically been a relative commercial failure.

Fig. 7: Obesity defined as BMI > 30

Classification of patients by BMI

Classification	BMI (kg/m ²)
Normal range	18.50 - 24.99
Overweight	≥ 25.00
- Pre-obese	25.00 - 29.99
Obese	≥ 30.00
- Obese Class I	30.00 - 34.99
- Obese Class II	35.00 - 39.99
- Obese Class III	≥ 40.00

Source: UBS

The US prescription weight-loss market continues to disappoint

Given the size of the market for supplements that help patients fight weight gain, the market for prescription weight-loss drugs has historically failed to live up to expectations. Prior to 2012, only one drug, orlistat had been approved for prescription use to fight obesity. Sales disappointed and orlistat was eventually switched from prescription to over-the-counter (OTC) status. More recently, the FDA has approved four new drugs since 2012. In our opinion, sales have disappointed relative to early hopes. Despite this, the US market for prescription weight-loss drugs still only reached around USD 500m in 2018, we estimate, up from around USD 100m in 2014.

The increasing acceptance of obesity as a disease was expected to lead to a greater willingness on the part of insurance companies to pay for weight-loss drugs, reducing the sometimes significant out-of-pocket costs that patients had to bear. But both patient and doctor awareness of treatment options has remained low, resulting in low sales of the three oral drugs launched in the 2012–14 time frame. Another problem dating back to the earlier failure of orlistat is patient compliance, since the benefits of treatment take time to appear, with patients potentially having to tolerate unpleasant side effects in the meantime. Despite improvements in treatment, these patient behavioral issues are difficult to change.

Since 2016, companies active in the space have increased efforts to build the market, including direct-to-consumer (DTC) marketing, where allowed.

Surgical solutions

Patients with BMI \geq 40 are candidates for bariatric surgery, which reduces the size of the stomach and/or restricts it to cut appetite and the ability to absorb food. We estimate a market in excess of USD 1bn annually, which we estimate could grow by a rate in the high single digits. However, the market leaders are diversified medtech companies, which makes it difficult to make a meaningful investment in this market, in our view.

Related conditions

Type 2 diabetes

Type 2 diabetes is the disease most highly correlated with obesity. While the latest research suggests that the causal relationships between the two conditions, and effects of other endocrine-related disorders, is complex and multi-faceted, it is undeniable that the global incidence of diabetes and obesity have risen in parallel. One meta-analysis of epidemiological studies found that high BMI raises the risk of developing diabetes by a factor of seven for men and a factor of 12 for women. We view diabetes as an attractive investment opportunity due to the availability of a number of relatively pure-play companies focused on diabetes drugs/insulin, and the oligopolistic nature of the insulin and GLP-1 markets.

Type 2 diabetes is a chronic, progressive, life-threatening disease that can be managed with treatment, but not cured. Treatment attempts to normalize the patient's blood sugar levels.

Initial treatment focuses on oral drugs designed to increase the amount of insulin made in the pancreas, or increase the patient's sensitivity to insulin. Over time these drugs lose effectiveness and the vast majority of patients will progress to insulin-dependency as their disease burden worsens. This creates predictable volume trends for insulin manufacturers.

We estimate the global insulin market at around USD 21bn in sales in 2018, a modest decline from 2017 given weak pricing dynamics in key markets like the US. We expect pricing to remain slightly negative, leading to a low-single-digit compound annual growth rate (CAGR) to 2023, despite mid-single-digit growth rate in patient numbers, higher treatment rates and the strong likelihood of progression of treated patients to insulin therapy.

Longer-term patient numbers growth should be in the low single digits in percentage terms (Fig. 8), but drug volumes should rise faster due to the current lack of diagnosis and treatment in emerging markets.


The global insulin market has three key players. This has driven down pricing that was already under pressure, as a perceived lack of differentiation between leading drugs led companies to fight for market share by granting ever-larger discounts to insurers. We believe the US market will eventually stabilize, but expect the majority of growth to shift to the GLP-1 market (see below). Mid-single-digit insulin volume growth should be almost entirely offset by negative pricing, with ex-US markets driving the total growth in the market. Volume growth is particularly strong in China, thanks to a combination of rising diabetes prevalence, better diagnosis rates, and broader insurance coverage.

As insulin growth has slowed, a new class of injectable insulin treatments known as Glucagon-like peptides (GLP-1) analogues has emerged as a key driver of overall diabetes sales. GLP-1 is a hormone secreted by the gut that helps the body control appetite and insulin levels. For patients still able to produce some insulin, GLP-1 drugs therefore have the important advantage that they promote weight loss, unlike direct insulin injections, which tend to lead to weight gain. Patients must still move to insulin treatment eventually, however, since GLP-1 only controls the effect of insulin, it does not produce it, although injections combining GLP-1 with insulin are a promising treatment option.

The GLP-1 market is dominated by the three large insulin manufacturers, although other companies are also present. GLP-1 drugs now account for around 14% of the diabetes market, with sales approaching USD 8bn in 2017. We expect aggregate GLP-1 sales to grow at mid double digits for the next five years, given the drug's weight-loss benefits which are driving wider adoption, before slowing to high single digits thereafter. Combined, insulin and GLP-1 sales should therefore grow in the mid-single digits for the foreseeable future.

Other related markets include oral antidiabetic drugs, a more fragmented segment, and products for blood glucose monitoring, which is an important part of day-to-day health management for diabetes

Fig. 8: Diabetes prevalence by region
2017 & 2045e, millions of people



Source: International Diabetes Federation. IDF Diabetes Atlas, 8th ed. Brussels, Belgium: International Diabetes Federation, 2017. <http://www.diabetesatlas.org>. Note: reduced estimates of diabetes prevalence compared to the previous edition may reflect changes to data sources rather than a real change in underlying diabetes prevalence.

patients. One research aim for continuous glucose monitoring companies is to develop an artificial pancreas, although significant technical challenges must still be overcome that look to prevent it from becoming a commercial reality in the foreseeable future.

Vision-related complications of diabetes

Diabetes leads to a variety of macro and microvascular complications. One microvascular complication of particular note is diabetic macular edema (DME), caused when fluid accumulates in the central part of the eye (the macula) due to damage to retinal blood vessels. This fluid impairs the patient's ability to focus and achieve sharp vision. If untreated, DME can lead to moderate vision loss and potentially blindness. While DME may take a long time to emerge, up to 30% of diabetes patients may ultimately suffer from the condition.

There are several drugs available to treat DME, as well as some surgical options.

Kidney disease and dialysis

Kidney disease is highly correlated to obesity and diabetes: the National Kidney Foundation estimates that diabetes accounts for 44% of new cases of kidney failure. Chronic kidney disease (CKD) describes the progressive loss of kidney function until patients' kidneys can no longer remove toxins from the blood, leading to a rapidly fatal build-up of waste products in the body. This result is known as end-stage renal disease (ESRD) and is typically defined as 10% or less of normal kidney function remaining. ESRD patients require dialysis three times per week to stay alive.

We estimate that the US dialysis services market alone was worth USD 26bn in 2018. Volume growth dynamics are similar to the insulin market: US patient numbers growth has been in the 3%–4% range most years since 2000, according to the United States Renal Data System (USRDS), while on a global basis patient numbers grow around 6%; we expect these trends to continue. Key opportunities for dialysis companies include volume growth in emerging markets as the ability to pay for this expensive treatment improves, and potentially the opening up of the Japanese market to foreign companies. Including sales of dialysis products (USD 16bn globally) and the smaller international services market, we estimate the total global market opportunity exceeds USD 40bn. Longer term, we estimate the growth opportunity in the mid-single digits.

Like the insulin market, the dialysis market is attractive as an investment opportunity due to consistent patient demand, high barriers to entry and an oligopolistic structure. Dialysis service companies exhibit some earnings cyclicality due to reimbursement dynamics and changes in the mix of commercial pay patients (very profitable) vs. Medicare (breakeven), but underlying volume trends are relatively stable.

The coming years could see major changes in how US dialysis patients are treated. In July 2019, the White House launched a kidney health initiative with the goal of 80% of new ESRD patients either receiving a kidney transplant or dialysis at home by 2025. Currently, around 30% of patients receive transplants and fewer than 10% get their

dialysis at home. But given the challenges of raising transplant rates, shifting dialysis out of clinics and into the home will likely be required to meet this target. This could pose challenges for providers who have invested heavily in dialysis centers and gain economies of scale from large patient numbers. However, home dialysis could in principle be more profitable than in-center dialysis given the lower treatment costs. Therefore, while the progress of the initiative bears watching, we do not yet see it as a threat to investors in dialysis service providers.

Fatty liver disease

The two related diseases, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are caused by an accumulation of fats in the liver. As inflammatory cells try to clear the fatty deposits, cirrhosis or scarring of the liver results, reducing liver function and potentially leading to the need for transplantation. NAFLD also increases cancer risk. NAFLD is believed to be linked to obesity and diabetes, but may also arise from other causes. There are currently no approved drugs to treat NAFLD, although a number of companies have candidates in late-stage development. In our view, it is difficult to assess the market opportunity at this stage: a large number of people are thought to have NAFLD, especially in the early, asymptomatic stage of the disease, but most remain undiagnosed. Even once symptoms are identified, a highly invasive diagnostic procedure means treatment is likely to be confined to late-stage disease in practice.

Cardiovascular and other related diseases

Obesity is associated with a wide range of additional co-morbidities, but from a medical perspective, cardiovascular disease (including heart failure and stroke) is among the most significant. According to a meta-analysis published in 2009 (source: *BMC Public Health*), being obese increases the risk of hypertension by 80% for men and 140% for women, the risk of congestive heart failure by 80% and of stroke by approximately 50% regardless of gender. Other common co-morbidities of obesity include high cholesterol levels, respiratory disorders including asthma and obstructive sleep apnea, cancer, psychological and neurological disorders, musculoskeletal disorders including osteoarthritis, and reproductive disorders. With the exception of sleep apnea (shortness of breath during sleep, a USD 5bn annual market), there are few direct investment opportunities in these areas and we see them as suboptimal ways to invest in the obesity theme.

Managing obese patients

The increasing size of obese patients poses a physical as well as monetary challenge to the hospital system. Extra-large patients require special equipment, for example beds and trolleys capable of handling up to 300kg in weight. While we see increased demand for these products, there are currently no companies with a meaningful earnings exposure.

Earnings growth outlook

We expect the underlying trends of urbanization and rising GDP per capita in emerging markets to continue for decades. Meanwhile, in developed markets, although consumers have an ever-increasing

choice of healthy food and fitness options, behavior changes slowly at the societal level, and obesity rates have at best stabilized. We therefore expect the market opportunity for companies targeting the prevention and treatment of obesity to continue growing above global GDP for an extended time.

Link to Sustainable Investing

The third UN sustainable development goal (SDG), good health and wellbeing, calls for reducing mortality rates attributed to cardiovascular disease and for strengthening the capacity for early warning, risk reduction and management of national and global health risks. Obesity is a major risk factor for a number of chronic diseases, including diabetes, cardiovascular disease and cancer. As obesity rates rise in developing countries, so too will the need for healthcare services. Obesity is also relevant to SDG 2 “Zero Hunger” as lack of food security can have a direct impact on rates of obesity. Due to their long shelf life, processed foods can be transported and stored for longer before spoiling. While low in nutritional value, processed foods offer a higher energy content at a lower cost than non-processed, fresh alternatives.

Helping prevent obesity and treating obese patients earlier and more effectively contributes to improving their life quality and expectancy. It also contributes to prevent adverse psychological consequences such as anxiety and depression. From an economic perspective, treating obesity is expected to be a leading contributor to the expansion of per capita healthcare spending in emerging markets. Better treatment of obesity will help already stretched healthcare budgets go further, enabling more patients to be treated and improving access to healthcare, particularly in the developing world.

*Rachel Whittaker, Sustainable Investing Strategist
Melissa Spinoso, Sustainable Investing Analyst*

Conclusion

We expect the underlying trends of urbanization and rising GDP per capita in emerging markets to continue for decades. In developed markets, there is some evidence obesity rates are stabilizing, but we think they are unlikely to go into reverse any time soon. Therefore, we expect the market opportunities for companies targeting the prevention and treatment of obesity to continue growing above GDP for an extended time. This should provide a lasting opportunity for companies exposed to the theme to achieve above-market earnings growth rates and returns on capital, on average. We recommend a diversified exposure to minimize stock-specific risks associated with drug development.

Risks

Human behavior changes little and we see continued demand for the products and services of the healthy food and healthcare industries. Perhaps the biggest risk to the overall theme would be the development of a medical breakthrough that would turn obesity from a chronic to a curable condition. Biotechnology companies are

exploring gene therapy approaches with this goal, but we do not anticipate breakthroughs in the foreseeable future.

Considering the broader investing environment, both the healthcare and the broader food and beverage sector are sensitive to changes in interest rates, typically underperforming when bond yields rise.

Specific risks include:

- **Healthy food industry:** changes in food and drink fashions can impact sales trends either positively or negatively. We view changes in government health policy as likely to favor the healthy food industry. Companies can also be affected by product recalls, although these are unusual.
- **Sportswear and apparel:** changes in fashion trends can change the demand for particular brands.
- **Pharmaceutical companies:** clinical trial failures, product recalls and litigation are standard risks in the pharma industry. Moreover, new treatments may be developed that make existing products obsolete. This is particularly true of development-stage pharmaceutical and biotech companies. As discussed above, the market for prescription anti-obesity drugs in particular has a history of failing to meet commercial expectations due to patient non-compliance, side effects and a lack of insurance reimbursement. For this reason we prefer the diabetes, dialysis and certain medtech markets.
- **Medical products:** government-reimbursed products could face pricing pressure as healthcare budgets are increasingly stretched, including in the emerging world.

What does this mean for entrepreneurs?

Employees are an important economic factor contributing to a company's success. Entrepreneurs therefore have an interest in supporting and maintaining the health of their employees. In the past, this concept was often limited to occupational health and safety concerns in the workplace, but newer research has taken a more values-based approach and argued that work should maintain or even improve employee health. This includes physical, mental and emotional health, in our view.

The physical health of employees therefore plays a central role in a company's success and, as explained above, careful weight management helps to reduce the risk of a wide range of illnesses and complications. In fact, obesity has been shown to lead to both absenteeism and presenteeism, as well as higher levels of short-term disability and workers' compensation claims. Entrepreneurs could therefore benefit from helping their employees monitor and manage their weight by careful selection of benefits that encourage healthy behavior, or as part of a broader program of workplace health and wellness. This goal corresponds broadly to the "prevention" measures described in this report.

Specifically, entrepreneurs operating a canteen can offer more healthy menus, for example replacing french fries and other fried food with more variety on the salad buffet. Similarly, vending machines can

be re-stocked with healthier options, and entrepreneurs could consider offering cooking evenings to help employees preparing healthier meals at home. Second, entrepreneurs can provide incentives for their employees to do more sport, such as contributing to employees' gym membership. Larger companies could even co-ordinate sport events, e.g. running groups, which may have the additional benefit of increasing loyalty as well as improving employees' health.

Health and well-being programs have now been widely adopted by large companies (for example, a 2013 Hewitt study showed that 85% of US large corporates already offered them) and have been shown to increase employee satisfaction, engagement and commitment. The data collected by programs' operators, when carefully anonymized, can give employers a snapshot of their employees', and thus their firm's, health.

Finally, in regions where employers contribute financially to the direct costs of their employees' health, such as the US, keeping employees healthy has a direct effect on the bottom line.

The good news is reducing weight by just 5%-10% has been shown to improve health across a number of metrics, including reducing blood pressure and cholesterol, preventing diabetes and heart disease, and improving sleep through lower incidence of sleep apnea. Given this central position of an employees' weight in their overall health, helping staff manage their weight could lead to lower direct and indirect costs for entrepreneurs, as well as a healthier, more committed and satisfied workforce. For more information, please refer to our White Paper "Corporate Health", published 2 November 2017.

Appendix

UBS Chief Investment Office's ("CIO") investment views are prepared and published by the Global Wealth Management business of UBS Switzerland AG (regulated by FINMA in Switzerland) or its affiliates ("UBS").

The investment views have been prepared in accordance with legal requirements designed to promote the **independence of investment research**.

Generic investment research – Risk information:

This publication is **for your information only** and is not intended as an offer, or a solicitation of an offer, to buy or sell any investment or other specific product. The analysis contained herein does not constitute a personal recommendation or take into account the particular investment objectives, investment strategies, financial situation and needs of any specific recipient. It is based on numerous assumptions. Different assumptions could result in materially different results. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for sale to all investors. All information and opinions expressed in this document were obtained from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to its accuracy or completeness (other than disclosures relating to UBS). All information and opinions as well as any forecasts, estimates and market prices indicated are current as of the date of this report, and are subject to change without notice. Opinions expressed herein may differ or be contrary to those expressed by other business areas or divisions of UBS as a result of using different assumptions and/or criteria. In no circumstances may this document or any of the information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes (i) valuation or accounting purposes; (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or (iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees. By receiving this document and the information you will be deemed to represent and warrant to UBS that you will not use this document or otherwise rely on any of the information for any of the above purposes. UBS and any of its directors or employees may be entitled at any time to hold long or short positions in investment instruments referred to herein, carry out transactions involving relevant investment instruments in the capacity of principal or agent, or provide any other services or have officers, who serve as directors, either to/for the issuer, the investment instrument itself or to/for any company commercially or financially affiliated to such issuers. At any time, investment decisions (including whether to buy, sell or hold securities) made by UBS and its employees may differ from or be contrary to the opinions expressed in UBS research publications. Some investments may not be readily realizable since the market in the securities is illiquid and therefore valuing the investment and identifying the risk to which you are exposed may be difficult to quantify. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, divisions or affiliates of UBS. Futures and options trading is not suitable for every investor as there is a substantial risk of loss, and losses in excess of an initial investment may occur. Past performance of an investment is no guarantee for its future performance. Additional information will be made available upon request. Some investments may be subject to sudden and large falls in value and on realization you may receive back less than you invested or may be required to pay more. Changes in foreign exchange rates may have an adverse effect on the price, value or income of an investment. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information.

Tax treatment depends on the individual circumstances and may be subject to change in the future. UBS does not provide legal or tax advice and makes no representations as to the tax treatment of assets or the investment returns thereon both in general or with reference to specific client's circumstances and needs. We are of necessity unable to take into account the particular investment objectives, financial situation and needs of our individual clients and we would recommend that you take financial and/or tax advice as to the implications (including tax) of investing in any of the products mentioned herein.

This material may not be reproduced or copies circulated without prior authority of UBS. Unless otherwise agreed in writing UBS expressly prohibits the distribution and transfer of this material to third parties for any reason. UBS accepts no liability whatsoever for any claims or lawsuits from any third parties arising from the use or distribution of this material. This report is for distribution only under such circumstances as may be permitted by applicable law. For information on the ways in which CIO manages conflicts and maintains independence of its investment views and publication offering, and research and rating methodologies, please visit www.ubs.com/research. Additional information on the relevant authors of this publication and other CIO publication(s) referenced in this report; and copies of any past reports on this topic; are available upon request from your client advisor.

Important Information about Sustainable Investing Strategies: Incorporating environmental, social and governance (ESG) factors or Sustainable Investing considerations may inhibit the portfolio manager's ability to participate in certain investment opportunities that otherwise would be consistent with its investment objective and other principal investment strategies. The returns on a portfolio consisting primarily of ESG or sustainable investments may be lower than a portfolio where such factors are not considered by the portfolio manager. Because sustainability criteria can exclude some investments, investors may not be able to take advantage of the same opportunities or market trends as investors that do not use such criteria. Companies may not necessarily meet high performance standards on all aspects of ESG or sustainable investing issues; there is also no guarantee that any company will meet expectations in connection with corporate responsibility, sustainability, and/or impact performance.

Distributed to US persons by UBS Financial Services Inc. or UBS Securities LLC, subsidiaries of UBS AG. UBS Switzerland AG, UBS Europe SE, UBS Bank, S.A., UBS Brasil Administradora de Valores Mobiliarios Ltda, UBS Aseores Mexico, S.A. de C.V., UBS Securities Japan Co., Ltd, UBS Wealth Management Israel Ltd and UBS Menkul Degerler AS are affiliates of UBS AG. UBS Financial Services Incorporated of Puerto Rico is a subsidiary of UBS Financial Services Inc. **UBS Financial Services Inc. accepts responsibility for the content of a report prepared by a non-US affiliate when it distributes reports to US persons. All transactions by a US person in the securities mentioned in this report should be effected through a US-registered broker dealer affiliated with UBS, and not through a non-US affiliate. The contents of this report have not been and will not be approved by any securities or investment authority in the United States or elsewhere. UBS Financial Services Inc. is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule") and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule.**

External Asset Managers / External Financial Consultants: In case this research or publication is provided to an External Asset Manager or an External Financial Consultant, UBS expressly prohibits that it is redistributed by the External Asset Manager or the External Financial Consultant and is made available to their clients and/or third parties. For country disclosures, [click here](#).

Version 05/2019. CIO82652744

© UBS 2019. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.